Nanoparticles in the ocular drug delivery

International Journal of Ophthalmology

Volumn 6, Issue 3, 2013, Pages 390-396

  Zhou, Hong Yan ^a   Hao, Ji Long ^a   Wang, Shuang ^a   Zheng, Yu ^a   Zhang, Wen Song ^b  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Drug delivery; Eye; Nanoparticles

Indexed keywords

EID: 84894575360     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.03.25     Document Type: Review

References (98)

1. Zarbin MA, Montemagno C, Leary J.F., Ritch R. Nanotechnology in ophthalmology. Can J Ophthalmol. 2010; 45(5): 457-476.
2. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010; 29(6): 596-609.
3. Kesavan K, Balasubramaniam J, Kant S., Singh PN, Pandit JK. Newer approaches for optimal bioavailability of ocularly delivered drugs: review. Curr Drug Deliv. 2011; 8(2): 172-193.
4. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm Sci Tech. 2009; 10(3): 808-819.
5. Baba K, Tanaka Y, Kubota A., Kasai H, Yokokura S, Nakanishi H., Nishida K. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye. J Control Release. 2011; 153(3): 278-287.
6. Maiti S, Paul S, Mondol R., Ray S, Sa B. Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation. AAPS Pharm Sci Tech. 2011; 12(2): 755-763.
7. Jung HJ, Chauhan A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials. 2012; 33(7): 2289-2300.
8. Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond) 2011; 25(5): 578-586.
9. Ensign LM, Schneider C, Suk J.S., Cone R., Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater. 2012; 24(28): 3887-3894.
10. Yang H, Tyagi P, Kadam R.S., Holden CA, Kompella UB. Hybrid Dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012; 6(9): 7595-7606.
11. Singh KH, Shinde UA. Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Pharmazie. 2011; 66(8): 594-599.
12. Chen R, Qian Y, Li R., Zhang Q, Liu D, Wang M., Xu Q. Methazolamide calcium phosphate nanoparticles in an ocular delivery system. Yakugaku Zasshi. 2010; 130(3): 419-424.
13. Wadhwa S, Paliwal R, Paliwal S.R., Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target. 2010; 18(4): 292-302.
14. Lütfi G., Müzeyyen D. Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application. Pharm Dev Technol. 2013; 18(3): 701-709.
15. Li R, Jiang S, Liu D., Bi X, Wang F, Zhang Q., Xu Q. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul. 2011; 28(2): 134-141.
16. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech. 2011; 12(4): 1087-1101.
17. Attama AA, Reichl S, Müller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res. 2009; 34(8): 698-705.
18. Tamilvanan S, Kumar BA. Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison with phospholipid-based anionic and neutral-charged nanosized emulsions. Drug Dev Ind Pharm. 2011; 37(9): 1003-1015.
19. Shao T, Li X, Ge J. Target drug delivery system as a new scarring modulation after glaucoma filtration surgery. Diagn Pathol. 2011; 6: 64.
20. Kalam MA, Sultana Y, Ali A., Aqil M, Mishra AK, Chuttani K. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target. 2010; 18(3): 191-204.
21. Vega E, Gamisans F, García ML, Chauvet A., Lacoulonche F, Egea MA. PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci. 2008; 97(12): 5306-5317.
22. Shen J, Sun M, Ping Q., Ying Z, Liu W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology. 2010; 21(2): 025101.
23. Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, Eldally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008; 31(8): 1040-1049.
24. Eljarrat-Binstock E., Orucov F, Aldouby Y., Frucht-Pery J, Domb AJ. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release. 2008; 126(2): 156-161.
25. Gokce EH, Sandri G, Bonferoni M.C., Rossi S., Ferrari F, Güneri T, Caramella C. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008; 364(1): 76-86.
26. Yenice I, Mocan MC, Palaska E, Bochot A., Bilensoy E, Vural I, Irkeç M, Hincal AA. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res. 2008; 87(3): 162-167.
27. Sandri G, Bonferoni MC, Gökçe EH, Ferrari F, Rossi S, Patrini M, Caramella C. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul. 2010; 27(8): 735-746.
28. Liu Z, Zhang X, Wu H., Li J, Shu L, Liu R., Li L, Li N. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm. 2011; 37(4): 475-481.
29. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine. 2009; 5(1): 90-95.
30. Zhu X, Su M, Tang S., Wang L, Liang X, Meng F., Hong Y, Xu Z. Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis. 2012; 18: 1973-1982.
31. Vega E, Egea MA, Calpena A.C., Espina M., García ML. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int J Nanomedicine. 2012; 7: 1357-1371.
32. Durairaj C, Kadam RS, Chandler J.W., Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci. 2010; 51(11): 5804-5816.
33. Contreras-Ruiz L., de la Fuente M, García-Vázquez C, Sáez V, Seijo B, Alonso MJ, Calonge M, Diebold Y. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. Cornea. 2010; 29(5): 550-558.
34. Nagarwal RC, Singh PN, Kant S, Maiti P., Pandit JK. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol. 2010; 6(6): 648-657.
35. Fei WL, Chen JQ, Yuan J, Quan D.P., Zhou SY. Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther. 2008; 24(2): 235-244.
36. Cho YK, Uehara H, Young J.R., Tyagi P., Kompella UB, Zhang X, Luo L, Singh N., Archer B, Ambati BK. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012; 53(4): 2328-2336.
37. Choi WI, Yoon KC, Im S.K., Kim YH, Yuk SH, Tae G. Remarkably enhanced stability and function of core/shell nanoparticles composed of a lecithin core and a pluronic shell layer by photo-crosslinking the shell layer: in vitro and in vivo study. Acta Biomater. 2010; 6(7): 2666-2673.
38. Li Z, Yao L, Li J., Zhang W, Wu X, Liu Y., Lin M, Su W, Li Y., Liang D. Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomedicine. 2012; 7: 1163-1173.
39. Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013; 39(4): 508-519.
40. Hattori M, Shimizu K, Katsumura K., Oku H, Sano Y, Matsumoto K., Yamaguchi Y, Ikeda T. Effects of all-trans retinoic acid nanoparticles on corneal epithelial wound healing. Graefes Arch Clin Exp Ophthalmol. 2012; 250(4): 557-563.
41. Klausner EA, Zhang Z, Chapman R.L., Multack RF, Volin MV. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials. 2010; 31(7): 1814-1820.
42. Konat Zorzi G., Contreras-Ruiz L, Párraga JE, López- García A, Romero Bello R, Diebold Y, Seijo B, Sánchez A. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol Pharm. 2011; 8(5): 1783-1788.
43. Chen YS, Alany RG, Young S.A., Green CR, Rupenthal ID. In vitro release characteristics and cellular uptake of poly (D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides. Drug Deliv. 2011; 18(7): 493-501.
44. Zorzi GK, Párraga JE, Seijo B., Sánchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol Biosci. 2011; 11(7): 905-913.
45. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci. 2008; 49(5): 2016-2024.
46. Contreras-Ruiz L., de la Fuente M, Párraga JE, López-García A, Fernández I, Seijo B, Sánchez A, Calonge M, Diebold Y. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis. 2011; 17: 279-290.
47. Sharma A, Tandon A, Tovey J.C., Gupta R., Robertson JD, Fortune JA, Klibanov AM, Cowden J.W., Rieger FG, Mohan RR. Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine. 2011; 7(4): 505-513.
48. Gupta H, Aqil M, Khar R.K., Ali A., Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target. 2011; 19(6): 409-417.
49. Gan L, Han S, Shen J., Zhu J, Zhu C, Zhang X., Gan Y. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm. 2010; 396(1-2): 179-187.
50. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008; 355(1-2): 307-313.
51. Kubinová S, Syková E. Nanotechnologies in regenerative medicine. Minim Invasive Ther Allied Technol. 2010; 19(3): 144-156.
52. Gomes Bittencourt M., Sepah YJ, Do D.V., Agbedia O., Akhtar A, Liu H, Akhlaq A., Annam R, Ibrahim M, Nguyen QD. New treatment options for noninfectious uveitis. Dev Ophthalmol. 2012; 51: 134-161.
53. Zhang L, Li Y, Zhang C., Wang Y, Song C. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomedicine. 2009; 4: 175-183.
54. Sakai T, Ishihara T, Higaki M., Akiyama G, Tsuneoka H. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011; 52(3): 1516-1521.
55. Hashida N, Ohguro N, Yamazaki N., Arakawa Y, Oiki E, Mashimo H., Kurokawa N, Tano Y. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp Eye Res. 2008; 86(1): 138-149.
56. Sakai T, Kohno H, Ishihara T., Higaki M, Saito S, Matsushima M., Mizushima Y, Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res. 2006; 82(4): 657-663.
57. de Kozak Y., Andrieux K, Villarroya H., Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E, Couvreur P. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004; 34(12): 3702-3712.
58. Sanders NN, Peeters L, Lentacker I., Demeester J, De Smedt SC. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J Control Release. 2007; 122(3): 226-235.
59. Janoria KG, Gunda S, Boddu S.H., Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007; 4(4): 371-388.
60. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010; 27(2): 117-134.
61. Bakri SJ, Pulido JS, Mukherjee P, Marler R.J., Mukhopadhyay D. Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model. Retina. 2008; 28(1): 147-149.
62. Zhang G, Feng X, Wabner K., Fandrey C, Naqwi A, Wiedmann T., Olsen TW. Intraocular nanoparticle drug delivery: a pilot study using an aerosol during pars plana vitrectomy. Invest Ophthalmol Vis Sci. 2007; 48(11): 5243-5249.
63. Chen J, Patil S, Seal S., McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol. 2006; 1(2): 142-150.
64. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010; 27(2): 117-34.
65. Schwartz SG, Flynn HW., Jr Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol. 2011; 12(3): 347-51.
66. Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011; 12(7): 1127-1131.
67. Koirala A, Makkia RS, Cooper M.J., Naash MI. Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells. Biomaterials. 2011; 32(35): 9483-9493.
68. Tamboli V, Mishra GP, Mitrat AK. Polymeric vectors for ocular gene delivery. Ther Deliv. 2011; 2(4): 523-536.
69. Du J, Shi QS, Sun Y, Liu P.F., Zhu MJ, Du LF, Duan YR. Enhanced delivery of monomethoxypoly (ethylene glycol)-poly (lactic-co-glycolic acid)-poly l-lysine NPs loading platelet-derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells. J Gene Med. 2011; 13(6): 312-323.
70. Read SP, Cashman SM, Kumar-Singh R. A poly (ethylene) glycolylated peptide for ocular delivery compacts DN A into NPs for gene delivery to post-mitotic tissues in vivo. J Gene Med. 2010; 12(1): 86-96.
71. Hayashi A, Naseri A, Pennesi M.E., de Juan E., Jr Subretinal delivery of immunoglobulin G with gold NPs in the rabbit eye. Jpn J Ophthalmol. 2009; 53(3): 249-256.
72. Mo Y, Barnett ME, Takemoto D, Davidson H., Kompella UB. Human serum albumin NPs for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007; 13: 746-757.
73. del Pozo-Rodríguez A, Delgado D, Solinís MA, Gascón AR, Pedraz JL. Solid lipid NPs for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm. 2008; 360(1-2): 177-183.
74. Farjo R, Skaggs J, Quiambao A.B., Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DN A nanoparticles. PLoS One. 2006; 1: e38.
75. Liu HA, Liu YL, Ma Z.Z., Wang JC, Zhang Q. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CN V model. Invest Ophthalmol Vis Sci. 2011; 52(7): 4789-4794.
76. Zhou X, Wong LL, Karakoti A.S., Seal S., McGinnis JF. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse. PLoS One. 2011; 6(2): e16733.
77. Kong L, Cai X, Zhou X., Wong LL, Karakoti AS, Seal S, McGinnis JF. Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol Dis. 2011; 42(3): 514-523.
78. Jin J, Zhou KK, Park K, Hu Y., Xu X, Zheng Z, Tyagi P., Kompella UB, Ma JX. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011; 52(9): 6230-6237.
79. Park K, Chen Y, Hu Y., Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009; 58(8): 1902-1913.
80. Kim JH, Kim MH, Jo D.H., Yu YS, Lee TG, Kim JH. The inhibition of retinal neovascularization by gold NPs via suppression of VEGFR-2 activation. Biomaterials. 2011; 32(7): 1865-18671.
81. Kalishwaralal K, Sheikpranbabu S, BarathManiKanth S., Haribalaganesh R, Ramkumarpandian S, Gurunathan S. Gold NPs inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells. Angiogenesis. 2011; 14(1): 29-45.
82. Karthikeyan B, Kalishwaralal K, Sheikpranbabu S., Deepak V, Haribalaganesh R, Gurunathan S. Gold NPs downregulate VEGF-and IL-1β-induced cell proliferation through Src kinase in retinal pigment epithelial cells. Exp Eye Res. 2010; 91(5): 769-778.
83. Strettoi E, Gargini C, Novelli E., Sala G, Piano I, Gasco P., Ghidoni R. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc Natl Acad Sci USA. 2010; 107(43): 18706-18711.
84. Patel SR, Lin AS, Edelhauser H.F., Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011; 28(1): 166-176.
85. Kim JH, Kim JH, Kim K.W., Kim MH, Yu YS. Intravenously administered gold NPs pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology. 2009; 20(50): 505101.
86. Kim H, Csaky KG. Nanoparticle-integrin antagonist C16Ypeptide treatment of choroidal neovascularization in rats. J Control Release. 2010; 142(2): 286-293.
87. Sakai T, Kuno N, Takamatsu F., Kimura E, Kohno H, Okano K., Kitahara K. Prolonged protective effect of basic fibroblast growth factor-impregnated NPs in royal college of surgeons rats. Invest Ophthalmol Vis Sci. 2007; 48(7): 3381-3387.
88. Ding XQ, Quiambao AB, Fitzgerald J.B., Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-NPs does not elicit toxicity in the mouse retina. PLoS One. 2009; 4(10): e7410.
89. Wielgus AR, Zhao B, Chignell C.F., Hu DN, Roberts JE. Phototoxicity and cytotoxicity of fullerol in human retinal pigment epithelial cells. Toxicol Appl Pharmacol. 2010; 242(1): 79-90.
90. Häfeli U.O., Riffle JS, Harris-Shekhawat L, Carmichael-Baranauskas A, Mark F, Dailey J.P., Bardenstein D. Cell uptake and in vitro toxicity of magnetic NPs suitable for drug delivery. Mol Pharm. 2009; 6(5): 1417-1428.
91. Winkler DA, Mombelli E, Pietroiusti A., Tran L, Worth A, Fadeel B., McCall MJ. Applying quantitative structure-activity relationship approaches to nanotoxicology: Current status and future potential. 2012: Toxicology.
92. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010; 29(6): 596-609.
93. Dombu CY, Betbeder D. Airway delivery of peptides and proteins using NPs. Biomaterials. 2013; 34(2): 516-525.
94. Cordray MS, Amdahl M, Richards-Kortum RR. Gold nanoparticle aggregation for quantification of oligonucleotides: Optimization and increased dynamic range. Anal Biochem. 2012; 431(2): 99-105.
95. Pannier AK, Segura T. Surface- and hydrogel-mediated delivery of nucleic Acid NPs. Methods Mol Biol. 2013; 948: 149-169.
96. Donaldson K, Schinwald A, Murphy F., Cho WS, Duffin R, Tran L, Poland C. The biologically effective dose in inhalation nanotoxicology. Acc Chem Res. 2012
97. Arora M, Chan EK, Gupta S, Diwan AD. Polymethylmethacrylate bone cements and additives: A review of the literature. World J Orthop. 2013; 4(2): 67-74.
98. Heidel JD, Schluep T. Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv. 2012; 2012: 262731.